P1558: EARLY-START DEFERIPRONE IN INFANTS/YOUNG CHILDREN WITH TRANSFUSION-DEPENDENT BETA THALASSEMIA: EVIDENCE FOR IRON SHUTTLING TO TRANSFERRIN—RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (START)

P1558: EARLY-START DEFERIPRONE IN INFANTS/YOUNG CHILDREN WITH TRANSFUSION-DEPENDENT BETA THALASSEMIA: EVIDENCE FOR IRON SHUTTLING TO TRANSFERRIN—RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (START)

Bibliographic Details
Main Authors:	F. Tricta, C. Fradette, N. Temin, A. Rozova, D. Lee, I. Cabantchik
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000849088.46934.99

Similar Items

S123: SAFETY AND EFFICACY OF EARLY-START DEFERIPRONE IN INFANTS AND YOUNG CHILDREN WITH BETA-THALASSEMIA (START STUDY)
by: M Elalfy, et al.
Published: (2022-01-01)

P1442: PRACTICE-BASED EVIDENCE: LONG-TERM SAFETY COHORT OF DEFERIPRONE IN PATIENTS WITH SICKLE CELL DISEASE FROM THE US REGISTRY
by: Sherif Badawy, et al.
Published: (2023-08-01)

A decisional algorithm to start iron chelation in patients with beta thalassemia
by: Fabrice Danjou, et al.
Published: (2014-03-01)

Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major
by: Khaled M. Musallam, et al.
Published: (2011-02-01)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
by: A. Piga, et al.
Published: (2022-06-01)

Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients
by: Nargesbeygom Mirbehbahani, et al.
Published: (2015-01-01)

S115: LONG-TERM EFFICACY AND SAFETY OF DEFERIPRONE FOR PATIENTS WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
by: B Inusa, et al.
Published: (2022-01-01)

S120: RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF DEFERIPRONE: SUBGROUP ANALYSIS OF PEDIATRIC PATIENTS IN IRON-OVERLOADED PATIENTS WITH SICKLE CELL DISEASE AND OTHER ANEMIAS
by: B Inusa, et al.
Published: (2022-01-01)

Deferiprone-induced arthropathy in thalassemia: MRI findings in a case
by: Gyan Chand, et al.
Published: (2009-04-01)

Deferiprone or deferasirox for cardiac siderosis in β thalassemia major (reply)
by: Alessia Pepe, et al.
Published: (2011-02-01)

P112: ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON--TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
by: K Kuo, et al.
Published: (2022-01-01)

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
by: Ricchi Paolo, et al.
Published: (2011-02-01)

Anthropometry in Children with Transfusion-Dependent Beta-Thalassemia Major
by: Noor Un Nisa, et al.
Published: (2023-12-01)

Significant Inverse Correlation of Serum Levels of Osteoprotegerin (OPG) and Transferrin Saturation in Thalassemia Dependent Transfusion (TDT) Patients
by: Indra Wijaya, et al.
Published: (2024-01-01)

The Best Iron Chelation Therapy in Major Thalassemia Patients is Combination of Desferrioxamine and Deferiprone
by: Ebrahim miri moghaddam, et al.
Published: (2011-04-01)

The Best Iron Chelation Therapy in Major Thalassemia Patients is Combination of Desferrioxamine and Deferiprone
by: Mohammad Ali Mashhadi, et al.
Published: (2011-06-01)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy
by: Capra Marcello, et al.
Published: (2011-02-01)

S270: LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDY
by: M. D. Cappellini, et al.
Published: (2022-06-01)

A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major
by: Yesim Aydinok, et al.
Published: (2007-12-01)

Molecular basis of transfusion dependent beta-thalassemia major patients in Sabah
by: Teh, Lai Kuan, et al.
Published: (2014)

Factors affecting endocrine complications in children with transfusion-dependent beta-thalassemia
by: Addyaa Shanker, et al.
Published: (2024-01-01)

Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia
by: Carla Casu, et al.
Published: (2016-01-01)

Women in the Star Chamber, 1558-1603
by: Ingersent, C
Published: (2024)

P1510: VAMIFEPORT PREVENTED THE FORMATION OF NON-TRANSFERRIN-BOUND IRON IN A MOUSE MODEL OF ΒETA-THALASSEMIA WITH BLOOD TRANSFUSIONS
by: N. Kalleda, et al.
Published: (2022-06-01)

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
by: Gotsis Efstathios D, et al.
Published: (2011-07-01)

The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload
by: El Alfy, M., et al.
Published: (2010)

Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study
by: Sebastian Botzenhardt, et al.
Published: (2018-01-01)

Endothelial dysfunction and inflammatory process in transfusion-dependent patients with beta-thalassemia major.
by: Aggeli, C, et al.
Published: (2005)

P1703: ECONOMIC BURDEN OF TRANSFUSION-DEPENDENT BETA-THALASSEMIA IN THE UNITED STATES
by: C. Udeze, et al.
Published: (2022-06-01)

Evaluation of Transfusion-Related Infections in Patients with Beta Thalassemia Major in Southeast Turkey
by: Esra Pekpak Şahinoğlu, et al.
Published: (2023-12-01)

Transfusion burden and willingness to pay for temporary alleviation of anemia status in transfusion-dependent beta-thalassemia patients in China
by: Shirui Chen, et al.
Published: (2024-10-01)

Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response
by: Yesim Aydinok, et al.
Published: (2012-06-01)

Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial.
by: Deepti Saxena, et al.
Published: (2016-01-01)

Sir Thomas Smythe (c. 1558-1625)
by: Archer, I
Published: (2007)

Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone
by: Paul T. Telfer, et al.
Published: (2009-12-01)

Feasibility study of starting a shuttle service from Johor Bahru to Desaru / Mohd Riza Abdul Halim
by: Abdul Halim, Mohd Riza
Published: (1989)

Non-transfusion-dependent thalassemias
by: Khaled M. Musallam, et al.
Published: (2013-06-01)

Correlations between Iron Load and CD4 in Adult Transfusion-Dependent Beta Thalassemia
by: Tubagus Djumhana Atmakusuma, et al.
Published: (2021-01-01)

P1464: CLINICAL COMPLICATIONS AMONG PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA IN GERMANY
by: Chuka Udeze, et al.
Published: (2023-08-01)

Anxiety, Depression, and Perceived Social Support in Patients with Transfusion Dependent Beta Thalassemia Major
by: Sumbul Asim, et al.
Published: (2023-12-01)